Keywords: rituxan, misses, ph, ii/iii, endpoint, sle, genentech

Rituxan misses Ph II/III endpoint in SLE

Article | 05 May 2008

Print This

Genentech and fellow USA-based Biogen Idec says that Rituxan (rituximab) missed its primary endpoint in a Phase II/III trial ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in